Share this article on:

The Possible Role of Corticosteroid Therapy for Pneumocystis Pneumonia in the Acquired Immune Deficiency Syndrome (AIDS).

Walmsley, Sharon; Salit, Irving E.; Brunton, James
Journal of Acquired Immune Deficiency Syndromes: August 1988
Original Article: PDF Only

Twenty-one episodes of Pneumocystis carinii pneumonia (PCP) and the acquired immune deficiency syndrome (AIDS) were treated with corticosteroids in the form of intravenous methylprednisolone or oral prednisone. A standard dose of 80 mg/day x 5 days was given for 15 episodes, whereas 6 patients received variable doses of 20-120 mg/day x 4-20 days. All were treated with trimethoprim-sulfamethoxazole (TMP-SMX). Comparison was made with 12 AIDS patients with PCP who were not treated with steroids. The steroid group was more severely ill than the controls as measured by alveolar-arterial oxygen difference but were otherwise comparable. Mortality from the pneumonia in the steroid group was (10%) vs. (25%) in the control group. Significant differences were seen in the following parameters: time to defervescence (1 day vs. > 9.3 days), the proportion of patients with pO2 > 70 mm Hg at day 5 [ (57%) vs. (9%)] and at day 10 [(90%) vs. (58%)], and number of adverse drug reactions [(19%) vs. x (75%)]. There were fewer late relapses (5%) vs. (22%)] after a 5.5 month (mean) follow-up. All patients had improvement in their clinical status when initially given corticosteroid therapy but early relapses occurred when steroids were discontinued in five patients (24%). No other complications could be attributed to steroid therapy in this study. A brief course of high-dose corticosteroids appears to be beneficial in severely ill AIDS patients with pneumocystis pneumonia. This suggests the need for randomized, double-blind, placebo-controlled trials to confirm these findings.

(C) Lippincott-Raven Publishers.